Retatrutide acts on three hormone receptors at once, GIP, GLP-1 and glucagon, and is being evaluated in clinical trials for obesity and related conditions. But there's no approved product to prescribe, FDA says pharmacies can't compound it, and FDA has acted against unapproved products marketed to consumers for human use [1]. What the drug is and what the trials found are covered in depth in retatrutide.
There is no FDA-approved retail retatrutide product
There is no FDA-approved retatrutide product for routine retail prescribing, and FDA says federal law bars using retatrutide in compounding. FDA's own page on unapproved GLP-1 drugs says: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition” [1].
Retatrutide does not appear on the reviewed FDA list of novel drug approvals for 2026 [2]. That ordinary-market restriction is different from an authorized investigational protocol, which has its own regulatory, sponsor and clinical safeguards.
| Route | Legal in the US? | Why |
|---|---|---|
| An ordinary retail prescription | No approved product | No FDA-approved retatrutide product exists [2] |
| A compounding pharmacy | No | “cannot be used in compounding under federal law” [1] |
| Routine telehealth retail sale | No approved product | FDA has warned telehealth companies for marketing it [1] |
| A consumer-marketed research vial for self-treatment | Not an authorized treatment route | FDA has acted against unapproved products marketed for human use [1] |
| Ordering an unapproved drug from overseas | Generally illegal for personal use | FDA says importing an unapproved drug for personal use is illegal in most circumstances [3] |
| An authorized clinical trial | Subject to enrollment and trial safeguards | Lilly's studies are listed on ClinicalTrials.gov [5] |
| Expanded access through your own doctor | Subject to sponsor, clinical and regulatory review | Lilly's single-patient program has strict criteria [6] |
A research-use label does not authorize consumer self-treatment
Some websites sell retatrutide labeled “for research purposes” or “not for human consumption.” FDA doesn't accept the label as a loophole when the product is sold to people with dosing instructions. In FDA's words, it “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption.’ These products have been sold directly to consumers for human use with dosing instructions” [1].
The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.[1]
“Unknown quality” is the practical problem. A seller’s research label or testing claim does not establish a legally marketed medicine, the identity of every vial or a safe sterile product for injection. If something goes wrong, there's no FDA-reviewed label to check it against. You can report a bad reaction to any product to FDA's MedWatch program [11].
A pharmacy can't compound it, and a prescription doesn't make it legal
Some people assume a doctor's prescription solves the problem. It doesn't. An ordinary prescription does not override the compounding restriction or replace authorization for investigational access. FDA lists three kinds of businesses it has warned over retatrutide [1]:
- telehealth companies, “for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers”
- drug-ingredient distributors, “for selling retatrutide and other GLP-1 drugs to compounders”
- outsourcing facilities, “for repackaging retatrutide”
An ordinary retail offer for compounded retatrutide is not the same as enrollment in an authorized study or a physician-requested expanded-access process. It's a different situation from compounded tirzepatide and semaglutide, which are ingredients of approved drugs and have distinct compounding restrictions. The legal status of compounded tirzepatide in 2026 is in is compounded tirzepatide still available.
Clinical trials provide a regulated investigational pathway
An authorized clinical trial is an identified investigational pathway for receiving retatrutide. A search of ClinicalTrials.gov on October 22, 2026 returned 33 registered records naming retatrutide, including an expanded-access record rather than only interventional trials. Two were recruiting: a phase 2 obesity study (NCT07467447) and a phase 3 master protocol in MASH, a fatty-liver disease (NCT07165028). Nine were active but no longer recruiting, and 21 were completed [5].
Trials have strict entry criteria, and the study team screens everyone. Many trials include a placebo group, so you may not receive the drug at all, and in a blinded study you may not know which group you are in. Counts change often, so search ClinicalTrials.gov for “retatrutide” and filter by recruiting status for the current list.
Expanded access exists, but only for a small group
FDA’s expanded access pathway, sometimes called compassionate use, may allow a patient with a serious condition get an investigational drug outside a trial when no comparable alternative exists and a trial isn't possible [4]. Lilly’s pre-approval expanded-access registry record is listed as available [6].
The program's listed criteria are narrow. The registry requires adults with BMI at least 35 despite adherence to and tolerance of the highest available dose of chronic weight-management therapy. They must have at least two serious or life-threatening obesity-related complications receiving standard care, be unable to join a retatrutide or comparable investigational trial, and must have discussed all standard options, including bariatric surgery. Requests come from the treating physician, not from patients directly, and availability depends on location, supply and an individual review [6]. A registry entry is not an individual eligibility decision or a guarantee that a request will be accepted. FDA also weighs whether potential benefit justifies risk and whether access would interfere with clinical development. Investigational use can be ineffective or cause unexpected serious harm [4].
What the trials have shown so far
In TRIUMPH-1, its first phase 3 obesity trial, retatrutide produced up to 25.0% average weight loss at 80 weeks, against 3.9% on placebo [8]. In people with obesity and type 2 diabetes, TRIUMPH-2 found up to 18.8% versus 5.1% [9]. Side effects were mostly digestive, and the phase 2 trial reported dose-related heart-rate increases that peaked at 24 weeks and declined after [7]. All four trials were funded by Eli Lilly.
| Trial | Who was studied | Doses the trial used | Result vs placebo |
|---|---|---|---|
| Phase 2 (2023) | 338 adults with obesity or qualifying overweight | 1 to 12 mg weekly | Up to −24.2% weight at 48 weeks vs −2.1% [7] |
| TRIUMPH-1 (2026) | 2,339 adults with obesity, no diabetes | 4, 9 or 12 mg weekly | −17.6%, −23.7% and −25.0% at 80 weeks vs −3.9% [8] |
| TRIUMPH-2 (2026) | 1,152 adults with BMI at least 27 and type 2 diabetes | 4, 9 or 12 mg weekly | −11.9%, −16.8% and −18.8% at 80 weeks vs −5.1% [9] |
| TRANSCEND-T2D-1 (2026) | 537 adults with type 2 diabetes on diet and exercise | 4, 9 or 12 mg weekly | HbA1c −1.69 to −1.94 points vs −0.81 at 40 weeks; weight −11.5% to −15.3% vs −2.6% [10] |
Doses are shown only as the trials used them. They are not a guide to taking anything. All four trials were funded by Eli Lilly.
FDA hasn't made an approval decision on retatrutide as of this update. How it compares with an approved drug is covered in retatrutide vs tirzepatide.
Approved options you can get now
Approved medicines containing tirzepatide or semaglutide are examples a clinician can consider today, subject to the particular product’s indication and your clinical circumstances. Tirzepatide acts on two of retatrutide's three receptors. Start with tirzepatide. Pharmacy-made versions have their own rules and risks, covered in compounded tirzepatide and compounded semaglutide, and the brand-versus-compounded question is in compounded tirzepatide vs Zepbound.